Taiwan Advance Bio-Pharmaceutical Inc. (TPEX:4186)
Taiwan · Delayed Price · Currency is TWD 10.30
-0.20 (-1.90%)
Aug 1, 2025, 2:59 PM CST
Accolade Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 353.49 | 315.43 | 276.9 | 239.59 | 231.92 | Upgrade |
Other Revenue | 0.68 | 0.56 | 41.34 | 3.77 | 3.65 | Upgrade |
| 354.17 | 315.98 | 318.24 | 243.36 | 235.57 | Upgrade | |
Revenue Growth (YoY) | 12.09% | -0.71% | 30.77% | 3.31% | 14.47% | Upgrade |
Cost of Revenue | 110.21 | 117.53 | 125.66 | 118.57 | 108.03 | Upgrade |
Gross Profit | 243.97 | 198.46 | 192.58 | 124.79 | 127.55 | Upgrade |
Selling, General & Admin | 180.64 | 177.47 | 168.04 | 182.08 | 172.67 | Upgrade |
Research & Development | 18.49 | 16.72 | 16.14 | 45.51 | 39.34 | Upgrade |
Operating Expenses | 202.71 | 196.02 | 184.97 | 227.59 | 212.01 | Upgrade |
Operating Income | 41.26 | 2.43 | 7.61 | -102.79 | -84.46 | Upgrade |
Interest Expense | -7.42 | -7.3 | -6.13 | -7.43 | -10.44 | Upgrade |
Interest & Investment Income | 1.45 | 1.49 | 0.5 | 0.12 | 0.14 | Upgrade |
Currency Exchange Gain (Loss) | 1.2 | 1.35 | 4.1 | -0.56 | -1.19 | Upgrade |
Other Non Operating Income (Expenses) | 0.17 | 0.31 | -3.47 | 0.38 | 2.75 | Upgrade |
EBT Excluding Unusual Items | 36.66 | -1.72 | 2.6 | -110.29 | -93.21 | Upgrade |
Gain (Loss) on Sale of Investments | -14.69 | -1.23 | 2.58 | 2.06 | 16.42 | Upgrade |
Gain (Loss) on Sale of Assets | -0.03 | 0.38 | 0.01 | -0.03 | 0.14 | Upgrade |
Asset Writedown | - | -9.15 | -1.89 | -6.05 | - | Upgrade |
Other Unusual Items | 0.66 | 0.33 | 0.39 | -0.14 | -6.48 | Upgrade |
Pretax Income | 22.6 | -11.39 | 3.69 | -114.44 | -83.13 | Upgrade |
Income Tax Expense | -0.27 | -0.71 | 0.52 | 4.08 | 3.26 | Upgrade |
Net Income | 22.88 | -10.68 | 3.17 | -118.53 | -86.39 | Upgrade |
Net Income to Common | 22.88 | -10.68 | 3.17 | -118.53 | -86.39 | Upgrade |
Shares Outstanding (Basic) | 90 | 90 | 90 | 90 | 81 | Upgrade |
Shares Outstanding (Diluted) | 90 | 90 | 90 | 90 | 81 | Upgrade |
Shares Change (YoY) | - | - | - | 11.05% | 6.92% | Upgrade |
EPS (Basic) | 0.25 | -0.12 | 0.04 | -1.32 | -1.07 | Upgrade |
EPS (Diluted) | 0.25 | -0.12 | 0.04 | -1.32 | -1.07 | Upgrade |
Free Cash Flow | 4.37 | 0.67 | -27.87 | -63.28 | -104.51 | Upgrade |
Free Cash Flow Per Share | 0.05 | 0.01 | -0.31 | -0.70 | -1.29 | Upgrade |
Gross Margin | 68.88% | 62.80% | 60.51% | 51.28% | 54.14% | Upgrade |
Operating Margin | 11.65% | 0.77% | 2.39% | -42.24% | -35.85% | Upgrade |
Profit Margin | 6.46% | -3.38% | 1.00% | -48.70% | -36.67% | Upgrade |
Free Cash Flow Margin | 1.23% | 0.21% | -8.76% | -26.00% | -44.36% | Upgrade |
EBITDA | 56.33 | 23.12 | 30.97 | -77.72 | -58.89 | Upgrade |
EBITDA Margin | 15.91% | 7.32% | 9.73% | -31.94% | -25.00% | Upgrade |
D&A For EBITDA | 15.07 | 20.69 | 23.36 | 25.07 | 25.57 | Upgrade |
EBIT | 41.26 | 2.43 | 7.61 | -102.79 | -84.46 | Upgrade |
EBIT Margin | 11.65% | 0.77% | 2.39% | -42.24% | -35.85% | Upgrade |
Effective Tax Rate | - | - | 13.98% | - | - | Upgrade |
Revenue as Reported | 354.17 | 315.98 | 318.24 | 243.36 | 235.57 | Upgrade |
Advertising Expenses | 16.99 | - | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.